Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Sanofi gains Kymab's KY1005 (Amlitelimab) to its pipeline, a fully human monoclonal antibody targeting key immune system regulator OX40L. Kymab’s pipeline also includes the oncology asset KY1044.
Lead Product(s): Amlitelimab
Therapeutic Area: Dermatology Product Name: KY1005
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,450.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition April 09, 2021
Details:
The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a varieties of immune-mediated diseases and inflammatory disorders.
Lead Product(s): Amlitelimab
Therapeutic Area: Dermatology Product Name: KY1005
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,450.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition January 11, 2021
Details:
A clinically meaningful improvement in disease activity was found compared to placebo, as measured by percentage of change from baseline in the Eczema Area and Severity Index (EASI) in patients inadequately controlled by topical corticosteroids from baseline to week 16.
Lead Product(s): KY1005
Therapeutic Area: Dermatology Product Name: KY1005
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
MC2-25 Cream is an effective isocyanate scavenger showing >90 % inhibition of protein carbamylation and counteracting the morphological skin changes induced by carbamylation as demonstrated in an in vitro reconstructed human uremic skin model.
Lead Product(s): MC2-25
Therapeutic Area: Dermatology Product Name: MC2-25
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
MC2-25 CKD-aP is formulated to be highly tolerable, moisturizing, convenient to use and it quickly absorbs into the skin allowing patients to get on with their life and their daily routines.
Lead Product(s): MC2-25
Therapeutic Area: Dermatology Product Name: MC2-25
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Seven of nine patients responded to rVA576 (nomacopan) with three, regarded as complete responders, showing >80% reduction in BPDAI (BP disease activity index)activity and four patients showing >70% reduction in pruritis by day 42; two of nine patients were non-responders.
Lead Product(s): Nomacopan
Therapeutic Area: Dermatology Product Name: rVA576
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
Sonelokimab is a novel tri-specific Nanobody® targeting IL 17A and IL-17F that also has an extended half-life and enhanced biodistribution through engineered binding affinity to albumin.
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
Sonelokinab is a novel investigational IL-17 A/F Nanobody® that neutralizes both IL-17A and IL-17F. The trial met its primary endpoint based on Investigator's Global Assessment at week 12 with clinically meaningful and statistically significant results for all tested doses.
Lead Product(s): Sonelokinab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The poster presentation will describe the safety & efficacy data from Akari’s Phase II clinical trial of nomacopan in adult patients with mild-moderate bullous pemphigoid. The PhII data was the basis for the agreement of the FDA & EMA that Akari may proceed to a PhIII study.
Lead Product(s): Nomacopan
Therapeutic Area: Dermatology Product Name: rVA576
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of disease remission on minimal oral corticosteroids (OCS).
Lead Product(s): Nomacopan
Therapeutic Area: Dermatology Product Name: rVA576
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
